Abstract We describe a female subject (DGAP100) with a 46,X,t(X;5)(p11.3;q35.3)inv(5)(q35.3q35.1)dn, severe psychomotor retardation with hypotonia, global postnatal growth restriction, microcephaly, globally reduced cerebral volume, seizures, facial dysmorphia and cleft palate. Fluorescence in situ hybridization and whole-genome sequencing demonstrated that the X chromosome breakpoint disrupts KDM6A in the second intron. No genes were directly disrupted on chromosome 5. KDM6A is a histone 3 lysine 27 demethylase and a histone 3 lysine 4 methyltransferase. Expression of KDM6A is significantly reduced in DGAP100 lymphoblastoid cells compared to control samples. We identified nine additional cases with neurodevelopmental delay and various other features consistent with the DGAP100 phenotype with copy number variation encompassing KDM6A from microarray databases. We evaluated haploinsufficiency of kdm6a in a zebrafish model. kdm6a is expressed in the pharyngeal arches and ethmoid plate of the developing zebrafish, while a kdm6a morpholino knockdown exhibited craniofacial defects. We conclude KDM6A dosage regulation is associated with severe and diverse structural defects and developmental abnormalities.
Introduction
Histone methylation is an epigenetic mechanism that plays an important role in regulation of global and tissue-specific gene expression at precise developmental stages (Berger 2007; Kouzarides 2007) . Different histone lysine (K) methylation states (mono-, di-, tri-; me1, me2, me3) are associated with gene transcriptional activation or repression depending on the location of the lysine residue. For example, histone H3 lysine 4 (H3K4) di-and tri-methylation are associated with gene activation, while H3K27 diand tri-methylation are associated with gene repression Martin and Zhang 2005; SantosRosa et al. 2002; Schuettengruber et al. 2007; Sims Iii et al. 2003) . Methylation sites are often found at promoters, insulators, enhancers and transcribed regions (Barski et al. 2007 ). Histone methylation is dynamic and regulated by specific methyltransferases and demethylases (Wysocka et al. 2005) .
Lysine-specific demethylase 6A (KDM6A; MIM 300128), previously designated as UTX, is both a histone lysine methyltransferase and demethylase (Lee et al. 2007) . It also plays a role in general chromatin remodeling (Miller et al. 2010 ). KDM6A interacts with mixed-lineage leukemia complex 2 (MLL2), in a conserved SET-1 like complex that trimethylates H3K4 , while also complexing with MLL3 and MLL4 although the function of these interactions is unknown (Lee et al. 2007 ). KDM6A contains six tetratricopeptide repeats (TPR) in the N-terminal portion of the protein, a JmjC domain and a novel zinc-binding domain, conserved in the KDM6 family, in the C-terminus. The JmjC domain is required for its demethylase activity. The proximity of the zinc-binding domain, which binds H3 residues 17-21, and the JmjC domain confers KDM6A-specific demethylase activity to H3K27me3/me2/me1 (Agger et al. 2007; Hong et al. 2007; Kim and Song 2011; Lan et al. 2007 ; Lee et al. 2007; Sengoku and Yokoyama 2011) .
KDM6A predominantly targets genes involved in developmental and cellular processes including cell adhesion, cytoskeletal organization, chromosome organization and biogenesis, transcriptional regulation, RNA splicing and the cell cycle. For example, in fibroblasts, KDM6A occupies 1,945 promoters, with most transcriptionally active genes marked with H3K4me2. In contrast, the target genes of H3K27me3 are inactive and enriched for involvement in development, such as HOX genes, which have previously demonstrated KDM6A regulation and activation during developmental stages (Agger et al. 2007; Lan et al. 2007 ; Lee et al. 2007; Wang et al. 2010) .
It is proposed that KDM6A plays a role at specific loci throughout development (Agger et al. 2007; Hong et al. 2007 ; Lee et al. 2007) . kdm6al is important for hox gene expression and posterior development in zebrafish, while Kdm6a is essential for proper cardiac and neural tube development in mice (Lan et al. 2007 ; Lee et al. 2012; Shpargel et al. 2012) . Drosophila dUTX mutants demonstrate rough eyes, dysmorphic wings and abnormal sex combs (Herz et al. 2010) . During embryogenesis KDM6A is involved in endoderm differentiation, the regulation of muscle-specific genes, as well as in activation of betaglobin in differentiated erythroid cells (Chaturvedi et al. 2009; Jiang et al. 2012; Seenundun et al. 2010 ). KDM6A has also been shown to play a role in the reestablishment of pluripotency in somatic cells and germ cell development (Mansour et al. 2012) .
Six individuals with Kabuki syndrome were recently identified with either point mutations or microdeletions encompassing portions of KDM6A (Lederer et al. 2012; Miyake et al. 2013 ). Kabuki syndrome is characterized by moderate intellectual disability, postnatal growth retardation, dysmorphic facial features (long palpebral fissures, with eversion of the lateral third of lower eyelids, high arched eyebrows, long lashes, broad and depressed nasal tip, large ears), clinodactyly, and recurrent otitis media in infancy. Additional anomalies can include skeletal and dental abnormalities, cleft palate, and persistent fetal finger pads (Kuroki et al. 1981; Niikawa et al. 1981) . The frequency of KDM6A mutations in Kabuki syndrome remains to be determined. Presently, mutations in MLL2 are recognized as the most common cause of Kabuki syndrome in 56-72 % of patients (Hannibal et al. 2011; Li et al. 2011; Micale et al. 2011; Ng et al. 2010; Paulussen et al. 2011 ).
We present a female subject with a complex chromosomal rearrangement that includes a balanced translocation between the X chromosome and an inverted region of chromosome 5. Although the phenotype of this individual overlaps with clinical features of Kabuki syndrome, her clinical findings exhibit greater morbidity. Using fluorescence in situ hybridization (FISH) and DNA sequencing, KDM6A was found disrupted in one of the translocation breakpoints; molecular genetic analyses were performed to explore further the role of KDM6A in development.
Methods

Subject recruitment
Informed consent, medical records and blood samples were obtained through an Institutional Review Board approved protocol of Partners HealthCare System titled ''Developmental Genome Anatomy Project'', and the subject received the study number DGAP100.
Generation of lymphoblast cell lines
A peripheral blood specimen was used for Epstein-Barr virus transformation as previously described (Bernacki et al. 2003) at Massachusetts General Hospital Genomics Core Facility in the Center for Human Genetic Research (Boston, MA).
Cytogenetic studies and array comparative genomic hybridization GTG-banded karyotyping was performed in the clinical work-up of DGAP100. For FISH, lymphoblast cells were harvested and metaphase spreads were prepared by standard protocols as previously described (Ney et al. 1993) . Fosmid (http://www.bacpac.chori.org/) and RP11 BAC clones were selected using the University of California Santa Cruz (UCSC) Genome Browser, GRCh37/hg19 assembly (http://www.genome.ucsc.edu). DNA extracted from clones was labeled with either SpectrumOrange or SpectrumGreen conjugated dUTP using a nick translation kit, according to the manufacturer's protocol (Abbott Molecular, Des Plaines, IL). Labeled pairs of probes were hybridized overnight to metaphase chromosome preparations. After 49 SSC/0.3 % Tween, 29 SSC/0.1 % Tween, and phosphate-buffered detergent washes, chromosomes were counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI, Abbott Molecular) and analyzed with a Zeiss Axioplan2 microscope (Thornwood, NY) with epi-fluorescence and Applied Imaging CytoVision software (Santa Clara, CA). An array comparative genomic hybridization (aCGH) experiment to assess genomic copy number in DNA extracted from peripheral blood lymphocytes was performed using an Agilent 1M array at the Cytogenetics Core of Dana Farber Harvard Cancer Center (Boston, MA).
Custom bar coded jumping library and sequencing DNA extracted from peripheral blood was sequenced using a customized whole-genome large insert jumping library for Illumina HiSeq2000, as previously described Talkowski Michael et al. 2011a, b) and analyzed with publicly available resources including BWA , SAMtools , and a C?? program, BamStat (http://www.mappingtools.chgr. org). All genome coordinates are listed as the GRCh37/ hg19 assembly.
X-inactivation study
Lymphoblast cells were synchronized for 15 h with 0.3 mg/ml thymidine (Sigma, Natick, MA), then washed three times in Hank's solution without Ca 2? /Mg 2?
(Invitrogen, Carlsbad, CA) and resuspended in complete RPMI medium (Invitrogen). 5-bromo-2 0 -deoxyuridine (BrdU, Sigma) was added to the culture to a final concentration of 30 lg/ml for 5.5 h prior to harvest. Slides were fixed in 70 % ethanol for 30 min, treated with 0.07 N NaOH for 45 s and washed with phosphate-buffered saline (PBS, Invitrogen). BrdU incorporation was detected with BrdU-AlexaFluor488-conjugated mouse monoclonal antibodies (Invitrogen) diluted to 1:35 in a 0.5 % Tween-20/ PBS solution. The anti-BrdU AlexaFluor488 solution was added to the slide and incubated for 30 min and then washed with PBS. Chromosomes were stained with DAPI.
RNA expression analysis of lymphoblastoid cells RNA was extracted from lymphoblastoid cell lines of DGAP 100 and two sex-matched controls (an 8-year-old female, GM03299, and a 16-year-old female, GM07533, obtained from the NIGMS Human Genetic Cell Repository, Coriell Cell Repositories, Camden, NJ) using the Qiagen RNeasy Mini Kit (Valencia, CA). Concentration and purity of RNA were assessed using a Thermo Scientific NanoDrop 1000 (Waltham, MA). First-strand cDNA synthesis using Superscript III First Strand Synthesis System for RT-PCR (Invitrogen) was prepared with 1 lg of total RNA. For quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR), primers were designed for use with probes from the Roche Universal Probe Library for genes of interest and for GAPDH (MIM 138400) as an internal control. All samples of cDNA were assayed in triplicate in 10 ll reaction volumes. Two control samples were analyzed for each replicate expression assay to ensure expression data were consistent. Quanta PerfeCta 2X qPCR Master Mix (Quanta Biosciences, Gaithersburg, MD), primers, probe and deionized water were mixed together in a fixed ratio, and 8 ll added to each well with 2 ll of *50 ng/ll cDNA. PCR conditions were the standard conditions of the CFX Real Time PCR Detection System (Bio-Rad, Hercules, CA). The cycle threshold (CT) was determined during the geometric phase of the PCR amplification plots, as recommended by the manufacturer. Relative differences in transcript levels were quantified using the 2 -DDCt method (Livak and Schmittgen 2001) . Acquired data were analyzed using Bio RadCFX Manager (Bio-Rad) and Microsoft Excel.
Evaluation of copy number variants in independent subjects
A copy number variant (CNV) burden analysis was performed as previously described (Talkowski Michael et al. 2012) . CNV data were compiled and analyzed from 33,573 clinical genome-wide microarray cases from the molecular Hum Genet (2013) (Ferreira et al. 2008; ISC 2008; O'Donovan et al. 2008; Purcell et al. 2009; Smith et al. 2009; Sullivan et al. 2008) and from the recently published cohort analysis of Cooper et al. (2011) that did not overlap with ISC controls (n = 6,113 after filtering WTCCC controls). Of these controls, only 6,239 were analyzed for CNVs on the X chromosome, and this reduced comparison group was used for analyses.
Zebrafish lines and maintenance
All embryos and fish were raised and cared for essentially as described (Westerfield 1993) , using established protocols as per the Subcommittee on Research Animal Care, Massachusetts General Hospital.
Cloning of the zebrafish kdm6a ortholog KDM6A orthologous candidate genes were identified in the zebrafish genome using the human KDM6A mRNA sequence and protein sequences, respectively (NCBI Reference Sequence: NM_021140.2, NP_066963.2), in the NCBI BLAST tool. The zebrafish gene with the greatest sequence homology is annotated as kdm6a (NCBI Reference Sequence: XM_692654.5 and XP_697746.2). The full-length 4.4 kb fragment was PCR amplified from 48 h post-fertilization (hpf) embryo cDNA using forward primer, 5 0 -CCGAGGATCCATGAAATCGTGCGGAGTGTC GG-3 0 and reverse primer 5 0 -CCGCTCGAGGCAACCCA TTTTTCTTTGTGA-3 0 . The amplified fragment was cloned into pGEM T-Easy Vector System (Promega, Madison, WI), and the resulting clone was verified by sequencing. This clone was used as a template to synthesize DIG-labeled antisense riboprobe for whole-mount RNA in situ hybridization. Full-length kdm6a cDNA was subcloned into a pCS7 expression vector for capped mRNA synthesis.
Whole-mount RNA in situ hybridization
Whole-mount RNA in situ hybridization was performed as described (Thisse and Thisse 2008) with digoxigeninlabeled antisense RNA probes generated using forward primer 5 0 -CCGAGGATCCATGAAATCGTGCGGAGTG TCGG-3 0 and reverse primer 5 0 -CGCGGATCCAATTAAC CCTCACTAAAGGGACAACACACCGATTGAGCAC-3 0 , respectively, using T3 polymerase. Sense RNA probes were generated using forward primer 5 0 -TAATACGACT CACTATAGGGATGAAATCGTGCGGAGT-3 0 and reverse primer 5 0 -ACAACACACCGATTGAGCAC, respectively, using T7 polymerase. Stained embryos/larvae were imaged using a Nikon AZ100 microscope and processed with NIS-Elements software, using the maximum intensity projection feature applied to z-stacks for greater depth of clarity.
Cartilage staining
Alcian blue staining was performed to analyze the craniofacial skeleton essentially as described (Walker and Kimmel 2007) and images were obtained on a Nikon 80i compound microscope.
Morpholino knockdown
Translation-blocking kdm6a and kdm6a-like morpholinos (MO) were designed by Gene Tools (Philomath, OR) with the following nucleotide sequence:
0 . Knockdown was performed injecting a 2 ng dose (1 nl) of morpholino into one-cell stage embryos, and the resulting phenotype was assessed at day 5 post-fertilization. We screened 24 hpf embryos for toxicity, determined by neural necrosis, which was below 10 %, and such embryos were excluded from analysis. Double morpholino knockdown was performed co-injecting smaller doses of kdm6a and kdm6a-like morpholinos in the same embryo. A total of 1 ng (1 nl of a 500 lM stock solution) of kdm6a and 1 ng (1 nl of a 250 lM stock solution) of kdm6a-like were injected, respectively. Capped full-length kdm6a mRNA was synthesized from pCS7:kdm6a plasmid using Sp6 mMessage mMachine kit (Ambion, Foster City, CA) and stored at -80°C. This stock solution was diluted to 150 ng/ll for rescue injections, and 2 ng kdm6a MO (1 nl) was co-injected with 150 pg (1 nl) kdm6a mRNA into one-cell stage embryos.
Results
Clinical history for DGAP100
DGAP100 is a 19-year-old female with a karyotypic interpretation of an apparently balanced translocation that we determined to represent a complex chromosomal rearrangement including a balanced inversion, 46,X,t(X;5) (p11.3;q35.3)inv(5)(q35.3q35.1)dn. She is nonverbal and has abnormal clinical findings of facial dysmorphia, large and slightly posteriorly rotated ears, repaired cleft palate, shovel-like teeth with caries, medial notches and enamel dysplasia, gingival hyperplasia, severe myopia, short stature, microcephaly, mild pectus excavatum, clinodactyly, puffy fingers with deep-set and hyperconvex nails, short metatarsals, neuromuscular scoliosis, cerebral atrophy with mild ventriculomegaly, hypotonia, history of seizures, and global developmental and severe psychomotor delay with intellectual disability (Fig. 1) . Facial dysmorphic features of DGAP100 include a flattened profile with a short columella, long and downslanting palpebral fissures with long eyelashes, and peaked, arched eyebrows. She also exhibits a thin upper lip with downturned corners of the mouth. After repair for a congenital high arched cleft palate performed at 9 months of age, she still has a poorly molded, short palate.
Family history
A three-generation pedigree of DGAP100 does not demonstrate similar abnormalities in any family members.
Birth DGAP100 was born after a 38-week uncomplicated pregnancy by Cesarean section for failure to progress. Birth parameters included a weight of 3,275 g (80th percentile), length of 48 cm (25th percentile), and head circumference of 33 cm (10th percentile). She demonstrated poor suckswallow and arousal responses, metabolic acidosis, and hypoglycemia. GTG-banded karyotyping was performed at 5 days of life revealing an apparently balanced translocation of Xp11.23 and 5q35. A brain MRI performed at 7 days after birth was normal.
General DGAP100 demonstrated growth retardation following birth; her height and weight deteriorated to the third percentile by 3 months. Failure to thrive was observed throughout infancy and DGAP100 remained in the third percentile for weight and height at 5 years and 11 months of age. By 8 years and 4 months, her weight dropped below the third percentile to four standard deviations below the mean with no progression in height. She has remained proportionately short at seven standard deviations below the mean. Head circumference centile has decreased steadily since birth and is currently 3.5 standard deviations below the mean.
Skin
At 5 years and 11 months, she had an eczematoid rash on her cheeks and thighs which still persists at 18 years of age. Her hands and feet become cyanotic and cool periodically. At 8 years of age, she had mild hypertrichosis and a 4 mm nevus surrounded by a lighter color halo, both on her back.
Ears, nose, throat, and eyes
At 5 years and 11 months DGAP100 passed an audiogram after a history of otitis media, otorrhea and hearing impairment. At 8 years of age, a cycloplegic retinoscopy revealed severe myopia (right eye: spherical -10.00 diopters, cylinder ?4.50 diopters, axis 110°; left eye: spherical -9.50 diopters, cylinder ?4.50 diopters, axis 75°).
Respiratory and cardiovascular
There were no abnormal respiratory findings except nasal congestion. Cardiovascular exam at 5 months identified a grade II systolic ejection murmur with regular rate and rhythm, which was assessed to be benign. Cardiovascular system evaluation was unremarkable at her later visits.
Gastrointestinal DGAP100 had feeding difficulties starting from birth and became gastronomy tube dependent for feeding.
Endocrine and metabolism
At 5 months she was admitted to the hospital due to failure to thrive, with chronic diarrhea since birth, dehydration, and chronic hypoglycemia. Chronic metabolic acidosis was determined to be secondary to chronic diarrhea. Testing for urine organic acids, reducing substances, and serum amino acids was normal, ruling out galactosemia and disorders of amino or organic acids.
Musculoskeletal
In addition to the described anomalies of the hands and fingers, mild pectus excavatum was noted at 8 years, and there was no scoliosis at the time. She was also treated with ankle orthotics for tight heel cords. At 8 years 3 months her bone age correlated to that of a female of 6 years 10 months according to Greulich and Pyle standards, identified by generalized demineralization and coarsening of the trabeculae in the osseous structures. By 16 years of age she developed neuromuscular scoliosis and subsequently underwent lumbar-sacral spinal fusion surgery at 17.5 years.
Neurologic DGAP100 has abnormal neurologic findings with severe global development delay since birth. At 9 days of life she had an abnormal neurological exam with decreased tone in lower extremities and hyperreflexia and hypertonicity in upper extremities. At 3 months, she had 3? deep tendon reflexes at the knees without clonus. At 5 months an upper gastrointestinal series showed swallowing incoordination and tracheal aspiration; poor sucking and swallowing motions were observed throughout infancy. CT scan of the brain performed at 10 months revealed prominent lateral and third ventricles suggesting mild ventriculomegaly while the electroencephalogram (EEG) was normal for her age. At 5 years and 11 months the EEG reported the waking record as mildly to moderately abnormal because of background slowing. She was nonverbal and nonambulatory except for rolling. Her facies moved symmetrically, all of her movements were slow, she tended to shake her legs, and she had brisk reflexes without spasticity. Of note, she was capable of demonstrating mirror hand movements and could walk ten steps with a walker at 8 years and 4 months of age. DGAP100 was diagnosed with intractable epilepsy at age 14. The longest seizure-free time period is 5-6 months since diagnosis. Her most recent MRI, at 16 years of age, revealed global cerebral volume loss and possible mucoceles of the sphenoid sinus. Now at 19 years of age, DGAP100 is still nonverbal with severe psychomotor retardation.
Medications
She is currently on antiepileptic, pain, and anti-inflammatory medications as well as vitamin D and calcium supplements. She takes her medicine through her gastronomy tube. Of note DGAP100 is allergic to sulfa drugs, Vancomycin, Ibuprofen and had Stevens-Johnson reaction to Trileptal.
Molecular and cytogenetic analyses of DGAP100
Karyotypic analysis in the newborn period was reported as 46,X,t,(X;5)(p11.23;q35)dn. aCGH results were interpreted as normal, and all copy number variants (CNVs) detected are present in the Database of Genomic Variants (DGV; http://www.projects.tcag.ca/variation/). FISH analysis identified two split clones: g248p80280c4 and g248p84552g9 (Fig. 2d) , narrowing the X chromosome breakpoint to within a 33 kb region disrupting KDM6A in the second intron. Because KDM6A escapes X inactivation (Greenfield et al. 1998) , an X-inactivation/late replication study was performed. The der(X) was determined to be active and the normal X chromosome homolog inactive (Fig. 3b) . Long range PCR was attempted to determine the breakpoint sequence, but was unsuccessful.
Whole-genome sequencing revealed loss of four bases at the chr 5 translocation breakpoint (chr 5:176906708-176906713) with inverted segments at both translocation breakpoints, suggesting the translocation was nested within an inverted genomic region. Consistent with this observation, an inversion between chr 5:170261000* and chr 5:178185000* was identified by the jumping library sequence data. The breakpoints of the inversion could not be delineated precisely to nucleotide resolution due to the presence of flanking segmental duplications, suggesting a mechanism of formation that includes nonallelic homologous recombination (NAHR). No genes or mRNA coding regions were disrupted by any of the three chromosome 5 breakpoints. The X chromosome breakpoint was found at chr X: 44759733 (Fig. 3a) , with loss of one base, disrupting the second intron of KDM6A and confirming the FISH mapping. The translocation breakpoints were Sanger sequenced for validation. KDM6A was the only gene directly disrupted as detected by sequence analyses. The next-gen cytogenetic karyotype for DGAP100 is designated as 46,X,der(X) (5qter-[178185000*::170261000*-[176906708::44759735-[Xqter),der(5)(5pter-[170261000*::178185000*-[ 176906713::44759733-[Xpter)dn[GRCh37/hg19] (Fig. 2a) .
Quantitative RT-PCR was performed to investigate expression of KDM6A. Relative differences in transcript levels were quantified and showed that KDM6A exhibited at least *60 % reduction of mRNA expression compared to control samples (Fig. 3c) , suggesting that the DGAP100 phenotype was caused by haploinsufficiency of KDM6A. In addition, the chromosome 5q35.3 translocation breakpoint is 6 kb upstream of DBN1 (MIM 126660) and 3.7 kb downstream of PDLIM7 (MIM 605903). Both DBN1 and PDLIM7 demonstrated expression reduced by *38 and *50 %, respectively, in DGAP100 lymphoblast cell lines compared to control cell lines (data not shown).
Evaluation of copy number variants in independent subjects
To strengthen our hypothesis of haploinsufficiency of KDM6A in the DGAP100 phenotype, we screened the microarray databases of SG and BCH (NDD and non-NDD cohorts), as well as DGV and DECIPHER (http://www. decipher.sanger.ac.uk/). Six individuals with a variety of neurodevelopmental abnormalities contained CNVs b RP11-962J7 spans the chromosome 5 translocation breakpoint and is found on chr 5, der(5) and der(X). c Three signals are also demonstrated for RP11-867J19, which spans the 5q35.3 inversion breakpoint. d G248P80280C4 spans the X chromosome breakpoint and hybridizes to chr X, der(X) and der(5) Hum Genet (2013) 132:537-552 543 encompassing KDM6A, two of whom were classified as autism spectrum disorder (Fig. 3a) . No CNVs were observed in controls, suggesting a statistically significant increase in CNV burden among cases with NDD (p = 0.04). To substantiate that these findings were not peculiar to technical differences in array technology between the clinical diagnostic NDD cohort and the control microarray studies, we compared the NDD cases to those analyzed on the same diagnostic arrays but without an indication of a neurodevelopmental disorder. No KDM6A disruptions were detected among the non-NDD cohort, replicating the initial observation (p = 0.04; case burden compared to combined control and non-NDD samples, p = 0.005). Three additional cases were identified in DECIPHER with two deletions and one duplication including KDM6A, while disruptions of exon 1 were noted in DGV. Five of the cases were female, two were male and the gender was unknown for the remaining two cases. Eight cases were diagnosed with intellectual disability, developmental delay or autism spectrum disorder. Two individuals demonstrated short stature, four suffered from seizures and three patients had dysmorphic features. Despite having a duplication, SG9651 also presented with wide-set and downslanting eyes, a short nose, clinodactyly, constipation, and most noticeably only had a vocabulary of 10 words at 4 years of age. DECIPHER130 had hypoglycemia and DECIPHER4479 was diagnosed with cleft palate, scoliosis, and eczema. Of note, KDM6A was the only gene within the minimal region of overlap in CNVs from all subjects, but was not the only gene involved in all subjects. It is thus possible that other loci may be contributory to the phenotypes in some individuals (Table 1) .
kdm6a expression in zebrafish
Zebrafish have two KDM6A homologs: kdm6a (ENSDARG 00000061759) and kdm6a-like (ENSDARG00000059794). Protein sequence alignments show that kdm6a (75 % sequence similarity) and not kdm6a-like (64 % sequence similarity) is the ortholog of KDM6A. The full-length kdm6a zebrafish homolog was cloned through RT-PCR and its spatiotemporal expression examined across different time points during embryogenesis. kdm6a demonstrated weak expression at early somite stages but robust expression thereafter. Expression of kdm6a was initially detected at 24 h post-fertilization (hpf) in the brain, otic placode and developing pharyngeal arches 1 and 2 (Fig. 4a asterisk, arrow and arrowheads, respectively). At 48 hpf, expression continued in the brain and in the first and second developing pharyngeal arches (Fig. 4b asterisk and arrowheads,  respectively) . By 72 hpf, kdm6a expression in the brain decreased but continued in the first and second pharyngeal arches as well as in the developing third pharyngeal arch (Fig. 4d 1, 2, 3) . At 96 hpf, expression was found in the ethmoid plate (Fig. 4e , arrowhead) and pharyngeal arches 2-7 ( Fig. 4f 2, 3 , 4, 5, 6, 7). The WISH using sense probe showed no staining as expected.
Craniofacial defects in kdm6a morpholino knockdown
To uncover the potential role of KDM6A in development, kdm6a in zebrafish was targeted by morpholino knockdown. Surviving embryos were followed until 96 hpf, a time point when all craniofacial structures should be fully formed, and the craniofacial cartilage was stained using Alcian blue. Knockdown of kdm6a resulted in embryos with a smaller lower jaw (Fig. 5e, k) , hypoplastic Meckel's cartilage, palatoquadrates, ceratohyals, diminutive ceratobranchials (Fig. 5h, k) , and the ethmoid plate failed to extend along its axis (Fig. 5n, q) . To verify the knockdown phenotype, specificity rescue experiments were performed injecting 150 pg/nl of wild-type kdm6a capped mRNA, resulting in an almost complete rescue of the phenotype in the majority of the cases (Fig. 5c , f, i, l, o, r). We further analyzed the phenotype with the stable transgenic line sox10::kaede, where the reporter protein is restricted to the neural crest lineage by the sox10 promoter (Dougherty et al. 2012) . We were able to assess kdm6a regulation of morphogenetic events by following migration of cranial neural crest cells (CNCC) in vivo across embryonic developmental stages. Although the mandible and the ceratohyals phenotype appeared similar to the Alcian bluestained morphants, the ceratobranchials were present but hypoplastic. CNCC can migrate to the pharyngeal arches 3-7, but the chondrocytes failed to terminally differentiate. Given the high sequence similarity of kdm6a and kdm6a-like homologs with human KDM6A and a possible overlap in function, we performed a double morpholino knockdown co-injecting smaller doses of kdm6a and kdm6a-like morpholinos in the same embryo, resulting in early death, thereby suggesting an early requirement during embryogenesis.
Discussion
We performed molecular genetic analyses for a 19-year-old female with multiple dysmorphic features and neurodevelopmental findings who has a balanced translocation that resulted in disruption of three non-genic regions on chromosome 5 and KDM6A on chromosome X. Analyses of gene expression revealed haploinsufficiency of KDM6A, and this gene was found to be the only locus within the minimal region of overlap from analyses of genomic alterations in nine independent individuals with similar phenotypic features to DGAP100.
The chromosomal rearrangement was complex with the chromosome 5 breakpoint nested within an apparent NAHR-mediated inversion. None of the chromosome 5 breakpoints directly disrupted genes, though dysregulation of nearby genes by positional effects might be contributing to the phenotype of DGAP100 and warrant consideration. The chromosome 5q35.3 translocation breakpoint lies in a region associated with Sotos syndrome (critical region: chr5:175130402-177456545). Sotos syndrome is characterized by excessive growth, macrocephaly, dysmorphic facial features, prominent jaw, mental retardation, and advanced bone age (Cole and Hughes 1994; Sotos et al. 1964; Tatton-Brown et al. 2005) . Mutations in or haploinsufficiency of NSD1 (MIM606681; chr5:176560080-176727214) are the etiologies in a large proportion of individuals with Sotos syndrome (Höglund et al. 2003; Kurotaki et al. 2002) . No statistically significant correlation between microdeletion size and phenotype has been reported (Tatton-Brown et al. 2005) , although some larger microdeletion cases had more severe mental retardation . In one reported case, a duplication downstream of NSD1 was speculated to cause reduced expression of NSD1, resulting in a Sotos phenotype (Kasnauskiene et al. 2011) . The chromosome 5q35.3 translocation breakpoint of DGAP100 (chr5:176906708-176906713) is near DBN1 and PDLIM7. These genes are within the critical microdeletion region, but have no known role in Sotos syndrome. In addition, deletions of DBN1 are present in three apparently healthy individuals in the DGV database. The DECIPHER database displays a predicted haploinsufficiency score, which considers genes with scores in the top 10 % as candidates contributing to the phenotype (Corpas et al. 2001; Huang et al. 2010 ). Haploinsufficiency scores for PDLIM7 and DBN1 are 78 and 43 %, respectively, suggesting neither locus is predicted to be a major contributing factor. Because DGAP100's phenotype does not correlate with that of Sotos syndrome, reduced expression of PDLIM7 and DBN1 by qRT-PCR most likely are non-contributory in her phenotype.
The 5q35.1 inversion breakpoint is *28 kb upstream of RANBP17 (MIM 606141) and *20 kb downstream of GABRP (MIM 602729), while the 5q35.3 inversion breakpoint is *27 kb upstream of ZNF354A (MIM 602444) and *7 kb downstream of AACSP1 (non-coding RNA). AACSP1 and GABPR expression were not measured because they are not expressed in lymphoblast cells, and RANBP17 and ZNF354A showed low expression that could not be quantified. In DECIPHER, ZNF354A received a haploinsufficiency score of 43 %, GABRP was 71 % and RANBP17 was 53 %, none of which are predicted to be pathogenic. Multiple CNVs are found in the DGV database spanning RANBP17. In addition, when analyzing the potential chromatin structure in the breakpoint regions in seven human cell lines using the UCSC Genome Browser, ''Integrated Regulation from ENCODE'' track (GRCH37/ hg19), there were no peaks indicating H3K4ME1, H3K4ME3 or H3K27Ac, which are indicative of promoters or other regulatory elements, at either inversion breakpoint. This suggests that no regulatory elements were disrupted or Functional and expression data from the zebrafish suggest that disruption of KDM6A represents a likely pathogenic defect in DGAP100. Translation-blocking morpholino disruption of kdm6a resulted in aberrant craniofacial development, while the body plan extended normally. It is not surprising that the phenotype included a significantly smaller lower jaw with hypoplastic Meckel's cartilage, palatoquadrates and ceratohyals and diminutive ceratobranchials 1-5 (pharyngeal arches 3-7), as kdm6a is specifically expressed in the pharyngeal arches. Meckel's cartilage and palatoquadrates are derived from the first pharyngeal arch. In zebrafish, Meckel's cartilage forms the mandible and the palatoquadrates articulate with the ethmoid plate, which is analogous to the amniote palate. The ceratohyals originate from the second pharyngeal arch and form part of the hyoid bone (Schilling and Kimmel 1997) . We also reproduced the phenotype of a previously published kdm6a-like morpholino knockdown zebrafish that resulted in abnormal posterior development. The knockdown did not have the typical chevron shape, exhibited a shortened caudal trunk, degeneration of the posterior notochord (somites 13-23), and slight dorsal curvature of the tail (Lan et al. 2007 ). Because both zebrafish homologs have high sequence similarity with human KDM6A mRNA, it is possible that duplication and subsequent specialization of KDM6A in zebrafish generated homologs with overlapping functions. Both kdm6a and kdm6al have a tetratricopeptide repeat-containing domain and a JmjC domain. Furthering this hypothesis, our kdm6a and kdm6al double morpholino knockdown model was embryonic lethal prior to gastrulation, suggesting requirement of kdm6a in early embryogenesis, consistent with observations of embryonic lethality in Drosophila and mouse knockouts (Herz et al. 2010; Lee et al. 2012) .
The craniofacial defects observed in the kdm6a zebrafish knockdown suggest the cleft palate and dysmorphic facial features seen in DGAP100 are attributable to KDM6A haploinsufficiency. kdm6a was expressed in the pharyngeal arches, and the cartilage structures that developed from them were abnormal in the morpholino knockdown. In human development, neural crest from the first pharyngeal arch gives rise to the lower jaw (mandibular prominence/ Meckel's cartilage) and part of the upper jaw (maxillary prominence/palatopterygoquadrate bar). Meckel's cartilage also forms the malleus, sphenomandibular ligament and the anterior ligament of the malleus, while the maxillary cartilage gives rise to the incus and alisphenoid bones. The first pharyngeal arch also contributes muscles for mastication and other bones of the lower face. Cartilage from the second and third pharyngeal arches forms the hyoid bone, which functions in both swallowing and vocalization. The second arch also forms the stapes of the middle ear, the styloid process of the temporal bone and the stylohyoid ligament. The fourth and sixth pharyngeal arches both contribute to formation of the larynx. If the human embryonic expression patterns parallel those seen in zebrafish, it is possible that DGAP100 has abnormal middle or inner ear structures that correlate with her recurrent otitis media history; abnormal development of the hyoid bone and larynx could potentially participate in poor coordination of the suck-swallow response as an infant and explain why she continues to be non-verbal at age 18. It is also of interest that kdm6a is expressed in the ethmoid plate/palate and disrupted function results in a short ethmoid plate, because DGAP100 was born with cleft palate. In mice, Kdm6a has enriched expression in the anterior region of the neural tube, ventricular zone of the caudal neural tube, neural crest cells and somites at E8.5; expression is enriched in the heart, myotome of the somites, limb buds, branchial arches, isthmus, cortex and eyes at E11.5 . Previous studies demonstrated that Kdm6a is expressed at significantly higher levels in the brain and other tissues of female mice compared to male mice across developmental time points. Although Kdm6a escapes inactivation, it was shown that the inactive X chromosome contributes less Kdm6a transcript than the active X chromosome in mice (Xu et al. 2002; Xu et al. 2008) . Furthermore, Kdm6a
-/-female mice did not survive past E10.5, while heterozygous mice were viable and fertile. Female knockout mice exhibited severe cardiac malformations, anterior neural tube closure defects, and were significantly growth retarded compared to wild-type littermates, while female heterozygous mice displayed , flat mount of the lower jaw (j-l) and ethmoid plate dissections (m-r) with a magnified view of the dissected ethmoid plate (p-r). kdm6a morpholino knockdown (b, e, h, k, n, q) resulted in a shortened ethmoid plate (n) with hypoplastic Meckel's cartilage, palatoquadrates and ceratohyals (k). Injection of wild-type kdm6a mRNA partially rescued the knockdown phenotype (c, f, i, l, o, r). Scale bars 100 lm. Graph representing number of injected embryos on the x axis and type of injection on the y axis with the wild-type phenotype is represented in dark purple and the morphant phenotype in light purple. MM mismatch morpholino, MO morpholino, M Meckel's cartilage, PQ palatoquadrate cartilage, CH ceratohyals, CB ceratobranchials 1-5 (color figure online) normal cardiac morphogenesis . Variation in phenotype severity was observed in the female knockout embryos (Shpargel et al. 2012) . Most male knockout mice also demonstrated embryonic lethality and severe developmental delay, but some lived until adulthood . Also of note, some heterozygous mice have eye phenotypes and malocclusion (S-K Lee, unpublished data).
The mouse knockout model demonstrates abnormal neurologic, cardiac, eye and dental development as well as enriched expression in tissues where DGAP100 has an abnormal phenotype, such as the myotome, cortex, limb buds and eyes. This supports an interpretation that reduction of KDM6A expression is responsible for the phenotypic findings of DGAP100. DGAP100 has overlapping phenotypes with those described in six patients with Kabuki syndrome including hypoglycemia, feeding difficulties in infancy, developmental delay, intellectual disability, hypotonia, arched eyebrows, long palpebral fissures and eyelashes, short columella and mild ear abnormalities (Lederer et al. 2012; Miyake et al. 2013) . Interestingly, in two female Kabuki patients described with microdeletions, the microdeletion is located on the inactive X chromosome (Lederer et al. 2012) , while DGAP100's derivative X chromosome, containing the disrupted copy of KDM6A, is the active X chromosome. Because it has been previously shown in mice that the active and inactive X chromosomes contribute disproportionate amounts of transcript, and the fact that DGAP100 had a greater than 50 % reduction in KDM6A expression, DGAP100 could potentially have a more significant reduction in expression, leading to a more severe phenotype than that observed in the microdeletion cases. In addition, positional effects of the chromosome 5 disruptions should be considered as potential phenotypic contributors implicated by expression analyses of the nearby genes.
We also identified nine patients with deletions or duplications including KDM6A who were not previously diagnosed with Kabuki syndrome, in addition to DGAP100. Seven of these subjects had duplications, some deemed pathogenic by the diagnostic laboratory. These patients displayed variable phenotypes with some overlapping clinical manifestations typically found in Kabuki syndrome such as cleft palate, abnormal dentition, hypoglycemia, developmental delay, intellectual disability, seizures, hypotonia and ophthalmologic problems (myopia, retinal coloboma). Differences in the severity of the phenotypes might be attributed to the sizes of the CNVs, as well as the involvement of other potential pathogenic genes (Table 1) . Interestingly, there were also phenotypic distinctions as none of the ten patients we describe presented with congenital heart defects, another common occurrence in Kabuki syndrome, nor did all of the subjects present with the classic facial features.
We conclude that KDM6A is critical in early development and that abnormal KDM6A dosage has variable manifestations in individuals, although tight regulation of its expression appears to be crucial for normal development. The impact of dosage effects and the specific mechanisms by which KDM6A orchestrates its role in development are likely complex and warrant a supplemental approach to achieve a deeper understanding.
